جستجوی استاد راهنمای دانشگاهی

Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.

• Genome Engineering
• Neurodegenerative Diseases
• Stem Cell Research
• +۵ مورد دیگر

Professor Martin Peifer is a computational cancer genomics researcher at the University of Cologne, where he leads the Department of Translational Genomics. He serves as Principal Investigator of the Peifer Lab, which focuses on developing computational methods to analyze cancer genome sequencing data. His work is deeply integrated with the Center for Data and Simulation Science and he is an active member of the International Cancer Genome Consortium and the Pan-Cancer Analysis of Whole Genomes project. Peifer's research interests center on computational approaches to understanding cancer biology, with particular emphasis on tumor evolution and genome instability mechanisms. His lab develops methods to analyze somatic genome alterations including point mutations, copy number changes, and rearrangements. They also create computational tools for integrative genome analyses, tumor evolution reconstruction, and single-cell sequencing data analysis (both RNA and DNA). His interdisciplinary team applies high-performance computing and machine learning to interpret complex cancer sequencing data, aiming to better understand tumorigenesis, clonal evolution, and therapy resistance. Analysis of Peifer's extensive publication record reveals a strong focus on neuroblastoma and lung cancer genomics, with particular attention to tumor evolution patterns and genomic instability mechanisms. His work spans multiple cancer types but maintains consistent themes of computational methodology development and application to understand cancer progression and treatment resistance. The publications demonstrate increasing sophistication in analyzing intra-tumor heterogeneity and clonal dynamics over time. Peifer leads an active research group including postdoctoral fellows (Joel Kaufmann, Dr. Stephanie Pabel, Agnieszka Rumińska) and PhD students (Magdalena Seiffert, Justinas Valiulis). His lab is involved in the Collaborative Research Center 1399 focused on Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer, indicating significant grant funding and collaborative research efforts. The Peifer Lab operates at the intersection of computational biology and cancer research, maintaining an interdisciplinary approach that combines bioinformatics, machine learning, and high-performance computing to address complex questions in cancer genomics. Their work has significant implications for understanding cancer evolution and developing more effective treatment strategies.

• Computational Cancer Genomics
• Tumor Evolution
• Genome Instability
• +۵ مورد دیگر

Professor Patrick Harter is a faculty member at the Institute of Neuropathology, Ludwig Maximilian University of Munich (LMU), where he leads research in neuro-oncology and molecular diagnostics of CNS tumors. His work focuses on glioblastoma, meningioma, and brain metastasis, with emphasis on epigenetic mechanisms like DNA methylation and metabolic adaptations in the tumor microenvironment. Research interests span: Molecular classification of brain tumors using DNA methylation profiling Therapeutic targeting of BRAF/MEK and PI3K/Akt/mTOR pathways Role of hypoxia and metabolic plasticity in treatment resistance Liquid biopsy development for non-invasive tumor monitoring His recent publications demonstrate a strong trend toward integrating epigenetic, metabolic, and immunotherapeutic approaches. Articles frequently explore: Novel biomarkers for tumor grading and prognosis Mechanisms of therapy resistance in gliomas Impact of tumor microenvironment on metastasis

• Neuro-oncology
• Neuropathology
• Glioblastoma
• +۳ مورد دیگر

Jakob Körbelin is a Principal Investigator at the University Medical Center Hamburg-Eppendorf (UKE), affiliated with the Faculty of Medicine and the II. Medical Clinic and Polyclinic. His research focuses on vascular biology, gene therapy, and neurological disorders, particularly targeting the blood-brain barrier using adeno-associated viral (AAV) vectors. He leads studies on pulmonary hypertension, neurovascular interactions, and genetic diseases like Niemann-Pick type C2. His work bridges basic science and translational medicine, emphasizing AAV engineering and therapeutic applications. Key research interests include endothelial cell biology, neuroinflammation, and the pathophysiology of vascular diseases. Notably, he received the UCCH Hubertus Wald Young Investigator Award 2013 for his contributions. His lab explores mechanisms of vascular dysfunction, gene delivery optimization, and the impact of viral vectors in treating rare diseases. Collaborations span molecular neurobiology, immunology, and translational oncology. Publications highlight breakthroughs in AAV-mediated therapies, such as reversing neurodegeneration in NPC2 models and identifying novel targets for pulmonary hypertension. Ongoing projects address microvascular brain pathology in SARS-CoV-2 infection and the role of transcription factors in vascular diseases.

• Gene Therapy
• Vascular Biology
• Neurology
• +۳ مورد دیگر

Dennis C. Sgroi, MD, is Professor of Pathology at Harvard Medical School and Executive Vice-Chair of Pathology at Massachusetts General Hospital (MGH), where he also serves as Director of Breast Pathology. He leads the Sgroi Laboratory within the Molecular Pathology Unit and the Krantz Family Center for Cancer Research at MGH. Education & Training: MD, University of Connecticut School of Medicine Residency, Massachusetts General Hospital Fellowship, Massachusetts General Hospital Board certified: Anatomic & General Pathology, American Board of Pathology Research Focus: Dr. Sgroi’s laboratory integrates multi-omics technologies to discover and validate molecular biomarkers that predict breast-cancer recurrence and therapeutic response. Core projects include the clinically-adopted Breast Cancer Index (BCI) assay (HOXB13/IL17RB), deciphering HOXB13-mediated tumor-microenvironment remodeling in ER-positive and triple-negative breast cancer, and developing combinatorial therapies targeting HOXB13/ERBB2 co-amplified tumors with BRCA1 loss. Clinical Impact & Guidelines: The BCI biomarker has been prospectively validated in multiple randomized trials (NSABP-B-42, Trans-aTTom) and is now incorporated into NCCN and ASCO treatment guidelines for extended adjuvant endocrine therapy in post-menopausal women with ER-positive breast cancer. Scientific Awards & Honors: While individual awards are not enumerated in the supplied text, the sustained funding of ~ $19 million in annual direct research costs attests to national peer-review recognition. Research Team & Collaborations: The Sgroi Lab includes post-doctoral fellows, graduate researchers, and staff scientists such as Marinko Sremac, PhD. Collaborative networks span Dana-Farber/Harvard Cancer Center Breast Cancer and Cancer Genetics Programs, NRG Oncology, and international genomic consortia.

• Breast Cancer Pathology
• Molecular Oncology
• Translational Cancer Research
• +۴ مورد دیگر

Dr. Karol Nowicki-Osuch is a Group Leader at the German Cancer Research Center (DKFZ) , leading a research group focused on tumorigenesis and molecular cancer prevention. His work emphasizes understanding early stages of gastrointestinal tumor development using multimodal techniques like single-cell RNA sequencing, organoid models, and spatial transcriptomics. Key research areas include the molecular mechanisms underlying Barrett's esophagus, gastric intestinal metaplasia, and the transition to adenocarcinoma. Collaborations span institutions in Germany, Poland, the UK, and the US. His team investigates how normal epithelial cells lose molecular identity and progress to precancerous states. Notable achievements include demonstrating that esophageal adenocarcinoma originates from gastric tissue and identifying novel mutational signatures using the mutREAD method. Current projects aim to develop early cancer detection strategies and in vivo models of tumor progression. Dr. Nowicki-Osuch supervises PhD students and employs cutting-edge technologies such as spatial transcriptomics and organoid platforms. His lab integrates computational biology with experimental approaches to address gaps in understanding clonal evolution and somatic mutations in gastroesophageal cancers.

• Cancer Biology
• Molecular Oncology
• Gastrointestinal Cancers
• +۳ مورد دیگر

Eunjung (Alice) Lee, PhD is an Associate Professor in the Division of Genetics and Genomics at Boston Children's Hospital and Harvard Medical School. She serves as a member of the Global Faculty at the University of Cologne, specifically affiliated with their Core Profile Area on Aging-Associated Diseases and the CECAD Cluster of Excellence focused on cellular stress responses in aging-associated diseases. Dr. Lee received her PhD in Bioinformatics from the Korea Advanced Institute of Science and Technology (KAIST), conducting research in integrative systems biology with Trey Ideker at the University of California, San Diego. She completed her postdoctoral training with Peter J. Park at Harvard Medical School. Her educational background combines computational expertise with biological applications, establishing her unique position at the intersection of bioinformatics and disease mechanisms. Dr. Lee's research program centers on elucidating the role of transposable elements and somatic mutations in human pathologies including cancer, aging processes, and neurodegenerative conditions. Her laboratory has pioneered computational methods for analyzing cancer whole genome and single-neuron genome sequencing data, making landmark discoveries about somatic retrotransposition in human cancers and the brain. Her team has demonstrated how transposons influence disease through multiple mechanisms including shaping cancer immunity, generating novel molecules via alternative splicing in human tissues and cancers, and contributing to rare diseases through RNA splicing alterations. Currently, her research focuses on developing intervention strategies targeting these mechanisms and investigating somatic mutation patterns in neurodegenerative conditions using cutting-edge single-cell genomic technologies. Analysis of Dr. Lee's publication record reveals a strategic progression from foundational discoveries about somatic retrotransposition in cancers to increasingly sophisticated investigations of genomic mosaicism across diverse disease contexts. Her work consistently bridges computational innovation with biological insight, with recent publications emphasizing single-cell resolution of somatic mutations in neurodegeneration and DNA repair disorders. The research demonstrates growing methodological sophistication and clinical relevance, particularly in connecting genomic instability mechanisms to potential therapeutic approaches. NIH New Innovator Award (DP2) recognizing high-impact, early-stage investigation Leadership of transposon analysis working group in the SMaHT (Somatic Mosaicism Across Human Tissue) Network, an NIH consortium Co-organizer of the inaugural Keystone meeting on somatic mosaicism (2025) Regularly invited speaker at major international conferences on transposons, genomics, and genetics Dr. Lee leads an active research program developing and applying computational genomics methods to investigate somatic genomic variation. Her laboratory maintains strong connections with the broader scientific community through leadership roles in national consortia and conference organization. She is actively shaping the emerging field of somatic mosaicism research, with particular emphasis on translating basic genomic discoveries into potential clinical applications for cancer and neurodegenerative diseases. Her work bridges multiple disciplines including computational biology, cancer genomics, neuroscience, and aging research.

• Transposable elements
• Somatic mutations
• Cancer genomics
• +۷ مورد دیگر

Phil H Jones is a Senior Group Leader at the Wellcome Sanger Institute and Programme Leader at the MRC Cancer Unit, University of Cambridge. He leads the Jones Group which focuses on understanding how cancer-associated DNA changes in normal stem cells alter their behavior, allowing them to spread through normal tissues—the critical first step toward cancer development. Institution: MRC Cancer Unit, University of Cambridge Research Program: Cancer, Ageing and Somatic Mutation Programme Professional Recognition: Fellow of the Royal Society, Fellow of the Academy of Medical Sciences Dr. Jones's research centers on how mutations that alter the competitive fitness of normal stem cells give mutant stem cells the ability to spread through normal tissues. His current work employs deep sequencing, advanced imaging, gene editing, and single-cell analysis to define how oncogenic mutations alter stem cell behavior during aging and the earliest stages of cancer development in skin and esophagus. His lab-based studies complement his clinical work at Addenbrooke's Hospital, where he treats patients with non-melanoma skin cancer. Analysis of his recent publications reveals a consistent focus on somatic mutations in normal epithelial tissues, particularly examining how specific mutations (such as those in p53, Notch1, and PIK3CA) confer competitive advantages to cells, enabling clonal expansion. His work demonstrates that normal tissues become extensively colonized by mutant cells with age, with some mutations increasing cancer risk while others may actually decrease it. A key finding across multiple publications is that mutant clones can outcompete and eliminate early-stage tumors, suggesting novel approaches to cancer prevention. Fellow of the Royal Society Fellow of the Academy of Medical Sciences Multiple high-impact publications in Nature, Science, and Cell journals Dr. Jones collaborates extensively with Cancer Research UK, the Department of Oncology at the University of Cambridge, and the Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. His research is highly translational, aiming to apply fundamental discoveries about somatic evolution in normal tissues to develop rational interventions that reduce cancer risk in high-risk patients. The Jones Group employs a multidisciplinary approach combining experimental biology with computational modeling to understand the evolutionary dynamics of mutant clones in aging tissues. The Jones Group operates within the Cancer, Ageing and Somatic Mutation Programme at the Wellcome Sanger Institute, utilizing advanced 3D culture methods, gene editing, live imaging, and single-cell analysis capabilities. Their research infrastructure supports studies of both skin epidermis and esophageal epithelium, with particular focus on how lifestyle factors (sun exposure, alcohol consumption) and aging influence the somatic mutation landscape of normal tissues.

• Cancer Biology
• Stem Cell Research
• Somatic Mutations
• +۵ مورد دیگر

Prof. Dr. Claude Becker is a faculty member at the Faculty of Biology, Ludwig Maximilian University of Munich , specializing in plant genetics and epigenetics. His research focuses on biochemical interactions in plant communities and the role of epigenetic marks in environmental adaptation. Specializations: Epigenetic regulation, allelopathy, plant-microbe interactions, DNA methylation dynamics Key Projects: Studying heritable phenotypic variation in clonal plants, analyzing stress-responsive epigenetic hotspots, and investigating gene cluster evolution in Oryza species. Recent publications highlight his work on transposable element dynamics, microbiome feedback mechanisms, and metabolic specialization in plant interactions. His research combines molecular biology with ecological perspectives to understand plant adaptation strategies. Contact: claude.becker@biologie.uni-muenchen.de

• Plant Epigenetics
• Plant-Microbe Interactions
• Allelopathy
• +۳ مورد دیگر

Prof. Korbinian Schneeberger is a full Professor of Computational Genetics and Genome Plasticity at the Ludwig Maximilian University of Munich , embedded within the Graduate School of Life Science Munich (LSM) . He leads a multidisciplinary team of bioinformaticians, biologists, and biotechnologists, all driven by a shared curiosity in genomic technologies and plant genome evolution. Contact: k.schneeberger@lmu.de . Research Focus: Genome plasticity and mutational dynamics across plant species Development and refinement of next-generation sequencing and assembly pipelines Comparative genomics, pan-genome construction, and structural variation Epigenetic regulation and transposon biology in plant genomes Meiotic recombination and crossover patterning in holocentric plants Application of single-cell and single-nucleus technologies to dissect gamete-level variation His laboratory develops widely-used bioinformatics tools—including SHOREmap , findGSE , SyRI , and plotsr —that enable the community to assemble, compare, and interpret plant genomes at unprecedented resolution. Recent work advances understanding of centromere evolution, adaptation to extreme soils, layer-specific somatic mutation patterns in fruit trees, and large-scale Arabidopsis population genomics. Scientific Output & Impact: Since 2015, Prof. Schneeberger has published more than 60 peer-reviewed articles, many appearing in top-tier journals such as Nature Genetics , Nature Plants , and Genome Biology . His 2025 studies already tackle the mutational landscape of Arabidopsis centromeres, scalable eQTL mapping in gametes, and the phased pan-genome of tetraploid potato, underscoring a trajectory at the forefront of plant genomic science. Funding & Collaborations: Research in the Schneeberger Lab is supported by multiple national and international grants, providing resources for high-throughput sequencing, computational infrastructure, and interdisciplinary training. The group actively collaborates with leading plant research centers worldwide, sharing data and tools to accelerate discoveries in crop improvement and evolutionary biology. Team & Environment: The lab operates as a vibrant, international environment with state-of-the-art wet-lab and computational facilities. Trainees and staff benefit from the rich ecosystem of LSM, including structured doctoral programs, career mentoring, and access to cutting-edge core facilities.

• Computational Genetics
• Genome Plasticity
• Plant Genomics
• +۶ مورد دیگر

Prof. Dr. Alexander Schönhuth is a Professor at Bielefeld University, affiliated with the Faculty of Engineering, the Center for Biotechnology (CeBiTec), and the Institute for Bioinformatics Infrastructure (BIBI). He leads the Genome Data Science Group and serves as Head of Microbial Analyses and Services at BIBI. His academic roles include serving on the Faculty Conference as Personal Deputy for Prof. Dr. Helge Rhodin and as a Member of the Habilitation Committee. He provides academic student advisory services for the Master of Science in Computer Science program. Prof. Schönhuth's research focuses on the intersection of bioinformatics, computational biology, and data science, with particular emphasis on genome data analysis and precision medicine. His work spans multiple domains including metagenome assembly, viral haplotype reconstruction, single-cell sequencing analysis, and the application of machine learning techniques to complex genetic diseases. He has developed numerous computational methods and tools such as StrainXpress, Strainline, VeChat, and ProSolo that address specific challenges in genomic data analysis. His recent publications reveal a strong trend toward integrating advanced machine learning approaches, particularly deep learning and graph-based methods, with genomic data analysis. His work bridges the gap between theoretical computational methods and practical applications in healthcare, especially in precision medicine and oncology. The research demonstrates a consistent focus on developing scalable, accurate computational methods for analyzing complex genomic datasets, with increasing attention to clinical applications. Prof. Schönhuth has secured significant research funding, including ongoing European Union support for the "Smart pathology slide scanner for diagnosis and patient-specific treatment recommendation in oncology" project (2025-2027) and previously completed the "ALgorithms for PAngenome Computational Analysis" (ALPACA) project (2021-2024), which was funded by the European Union under the Marie Skłodowska-Curie program. His research collaborations span multiple institutions across Europe including Centre National de la Recherche Scientifique, Comenius University Bratislava, Dutch Research Council, and others. He leads the Genome Data Science Group within the Faculty of Engineering and is closely associated with the Bielefeld Center for Data Science (BiCDaS). His laboratory work focuses on developing computational methods for genomic data analysis, with particular attention to strain-aware metagenome assembly, viral quasispecies analysis, and precision medicine applications. The group maintains strong connections with both computational and biological research communities, facilitating interdisciplinary approaches to complex genomic challenges.

• Bioinformatics
• Genome Data Science
• Computational Biology
• +۵ مورد دیگر

Thorsten Reusch is Professor and Head of Research Division for Marine Ecology at GEOMAR Helmholtz Centre for Ocean Research Kiel, affiliated with Kiel University. His research investigates evolutionary ecology in marine systems, focusing on species adaptation to climate change, host-parasite interactions, and marine genomics using model organisms including cod, corals, seagrasses, and comb jellies. Current projects examine seagrass restoration for blue carbon sequestration (SeaStore), adaptive evolution in modular species (AdaptAsex), and fisheries-induced evolution. Reusch coordinates international collaborations including the BIO-C3 project analyzing Baltic Sea biodiversity changes. His work combines genomic analyses with ecosystem modeling to predict coastal resilience under climate change scenarios.

• Evolutionary Ecology
• Marine Genomics
• Climate Change Adaptation
• +۲ مورد دیگر

Eunjung (Alice) Lee is an Associate Professor in Genetics and Genomics at Boston Children’s Hospital and Harvard Medical School. Her NIH-funded research investigates transposable elements and somatic mutations in cancer, aging, and neurodegeneration. Research Breakthroughs: Pioneered computational methods proving somatic retrotransposition in human cancers and neurons. Demonstrated how transposons shape cancer immunity and generate novel RNA isoforms through alternative splicing. Leadership: Leads transposon analysis for NIH's SMaHT Network and co-organizes the inaugural Keystone meeting on somatic mosaicism (2025). Received NIH New Innovator Award for high-impact genomic research.

• Genomics
• Transposable Elements
• Somatic Mutations
• +۳ مورد دیگر

Dr. David Adams is a Senior Group Leader at the Wellcome Sanger Institute where he leads the Experimental Cancer Genetics Laboratory within the Cancer, Ageing and Somatic Mutation Programme. He also serves as Co-lead of Cell & Molecular Biology at the Cambridge Cancer Centre. As a Fellow of both the Academy of Medical Sciences and the Royal College of Pathologists, Dr. Adams has established himself as a leading researcher in cancer genetics and genomics. Dr. Adams' research focuses on understanding how genetic alterations contribute to cancer development through high-throughput functional genetic screens in human cells and mice. His laboratory investigates several key areas including the Atlas of Variant Effects using saturation genome editing, the Genomic Atlas of Dermatopathology, combinatorial CRISPR screening for synthetic lethal targets, and host regulation of tumor growth. His work combines cutting-edge genomic technologies with computational biology to uncover fundamental insights into cancer biology. Analysis of Dr. Adams' recent publications (2023-2025) reveals a strong emphasis on cancer genomics, melanoma research, and functional validation of genetic variants. His work spans multiple cancer types with particular focus on skin cancers, while also exploring broader applications in ocular diseases, immunology, and therapeutic development. The research demonstrates increasing integration of multi-omics approaches, cross-species comparisons, and translational applications of basic genomic discoveries. Among Dr. Adams' notable scientific achievements are his Fellowship in the Academy of Medical Sciences, the Goudie Medal from the Pathological Society, and an ERC Synergy Grant. He is also a founding member of the Atlas of Variant Effects Alliance and co-chairs Genomel (The Genetics of Melanoma Consortium). Dr. Adams has graduated more than a dozen PhD students and mentored over 50 students and postdocs who now lead research groups worldwide or work in industry and the NHS. His laboratory has received significant funding from Cancer Research UK, the Medical Research Council, and the Royal Society, supporting his advocacy efforts for cancer genetic studies in low- and middle-income countries. The Experimental Cancer Genetics Laboratory utilizes large-scale genomic studies and genome editing technologies to identify cancer genes and explore their function. Dr. Adams co-heads the Sanger Excellence Programme for Black British scientists and is actively involved in promoting diversity and inclusion in scientific research.

• Cancer Genetics
• Genomics
• CRISPR Genome Editing
• +۴ مورد دیگر

Björn Schumacher is a Professor and Principal Investigator at the Institute for Genome Stability in Aging and Disease at the University of Cologne, affiliated with CECAD and CMMC. He holds the Chair for Genome Stability in Ageing and Disease and leads a research group focused on the molecular mechanisms of aging and genome maintenance. His research centers on the role of DNA damage in aging, employing C. elegans and mammalian models. Key interests include DNA repair pathways, the DREAM complex as a master regulator of somatic repair, germline-soma communication, transgenerational inheritance of DNA damage, and the development of biological age clocks like BiT Age. The recent publications highlight a strong trend in understanding systemic DNA damage responses, epigenetic regulation of repair, and the interplay between environmental stress and genome stability. His work bridges fundamental mechanisms with translational applications in aging-associated diseases and rare progeroid syndromes. Eva Luise Köhler Research Prize for Rare Diseases Innovation Prize of the State of North Rhine-Westphalia DFG Reinhart Koselleck Grant European Research Council (ERC) Grant Schumacher has advised PhD students including Najmeh Sotanmohammadi and Markus Doll. His research is supported by major grants, including ERC, DFG, and FP7 Marie Curie CodeAge network. He is speaker of DFG Research Unit FOR 5504 and co-Director of the Minerva Center at Bar-Ilan University. His lab, part of CECAD, investigates genome instability using C. elegans and mammalian systems, focusing on regulatory networks, stress signaling, and inter-tissue communication in aging.

• Genome Stability
• DNA Repair
• Aging
• +۱۲ مورد دیگر